Physician profile
Michael Warren Smith
NPI 1003830530
$2,302.40
in general payments reported to CMS, 2019-2025
41 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $41.72 · 2022: $85.79 · 2023: $570 · 2024: $669 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,998.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $312.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $201.78 | 2019-2025 | Ubrelvy |
| Pfizer INC. | $199.48 | 2023-2025 | |
| Lilly USA, LLC | $167.78 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $167.62 | 2019-2025 | Evenity, Prolia, Otezla |
| Novartis Pharmaceuticals Corporation | $150.92 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $76.26 | 2019-2024 | Farxiga, Airsupra |
| Boston Scientific Corporation | $71.80 | 2025 | Wavewriter Alpha Prime 16 |
| Shield Therapeutics INC | $67.58 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $64.80 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.67 | 2024-2025 | Xifaxan, Trulance |
| Insightec,INC | $51.98 | 2023 | Exablate |
| Bayer Healthcare Pharmaceuticals INC. | $48.48 | 2023-2024 | |
| Glaxosmithkline, LLC. | $48.01 | 2019-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $47.83 | 2019-2025 | Capvaxive, Gardasil 9 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $43.35 | 2023-2025 | Cologuard Collection Kit |
| Seqirus USA INC | $39.14 | 2024-2025 | Fluad, Flucelvax |
| Alexion Pharmaceuticals, INC. | $39.05 | 2024 | Strensiq |
| Phathom Pharmaceuticals, INC. | $27.35 | 2025 | Voquezna |
| Novavax INC | $26.63 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Baxter Healthcare | $25.71 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Otsuka America Pharmaceutical, INC. | $25.24 | 2025 | Rexulti |
| Abbott Laboratories | $24.81 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $24.46 | 2022 | |
| Eisai INC. | $22.01 | 2024 | |
| Zimmer Biomet Holdings, INC. | $21.68 | 2025 | Persona |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.62 | 2025 | Jardiance |
| Atland Pharmaceuticals, LLC | $21.27 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Idorsia Pharmaceuticals US INC | $19.80 | 2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $19.74 | 2025 | Opsumit, Uptravi |
| Daiichi Sankyo INC. | $17.87 | 2023 | Injectafer |
| Medicure Pharma INC. | $17.24 | 2025 | Zypitamag |
| Janssen Pharmaceuticals, INC | $17.22 | 2024 | Xarelto |
| Dexcom, INC. | $16.43 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $15.82 | 2024 | Veozah |
| Mannkind Corporation | $15.29 | 2023 | Afrezza |
| Optinose US, INC. | $14.67 | 2019 | |
| Lucid Diagnostics INC. | $14.48 | 2025 | |
| Aerin Medical INC. | $14.07 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.70 | 2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.